Aclaris Therapeutics, Inc. (ACRS)

1,3100 +0,0500 (+3,97%) Börsenschluss: 04:00PM EDT

Aclaris Therapeutics, Inc.

701 Lee Road
Suite 103
Wayne, PA 19087
United States
484 324 7933
https://www.aclaristx.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 86

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Neal S. Walker D.O., M.D.	Co-Founder, President, Chairman & Interim CEO	73,5k	N/A	1970
Mr. Kevin Balthaser	Chief Financial Officer	581,52k	N/A	1988
Dr. Joseph Monahan Ph.D.	Chief Scientific Officer	492,43k	N/A	1957
Mr. James Loerop	Chief Business Officer	570k	N/A	1965
Mr. Matthew Rothman J.D.	General Counsel & Corporate Secretary	N/A	N/A	N/A
Dr. Jon Jacobsen Ph.D.	Senior Vice President of Chemistry	N/A	N/A	N/A
Mr. Steve Tucker	Senior Vice President of Project Leadership	N/A	N/A	N/A
Mr. Ajay Aggarwal M.B.A., M.D.	Senior Vice President of Clinical Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Corporate Governance

Aclaris Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 8, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.